Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558 · View on ClinicalTrials.gov ↗
Study Summary
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Rescue Medications
- DRUG Sacituzumab tirumotecan
Study Locations (9)
Other
- Rambam Health Care Campus ( Site 1422) — Haifa
- Niigata Cancer Center Hospital ( Site 1608) — Niigata
- Seoul National University Hospital ( Site 2301) — Seoul
- Asan Medical Center ( Site 2305) — Seoul
- Linkou Chang Gung Memorial Hospital ( Site 2605) — Taoyuan District
Florida
- Mount Sinai Cancer Center ( Site 0029) — Miami Beach
Iwate
- Iwate Medical University Hospital ( Site 1610) — Shiwa-gun
Tokyo
- Cancer Institute Hospital of JFCR ( Site 1614) — Koto
Seoul
- Severance Hospital ( Site 2302) — Seodaemun-Gu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2026-02-16 |
| Est. Completion | 2033-02-25 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07318558
The ClinicalTrials.gov registry entry for NCT07318558 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 741 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions — of which Bevacizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07318558 reports 9 study locations spanning 5 distinct geographic areas — top geographies include Other, Florida, Iwate. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07318558 about?
NCT07318558 is a clinical study titled "A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)". Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us...
What is the current status of trial NCT07318558?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2026-02-16. Estimated completion is 2033-02-25.
What conditions does trial NCT07318558 study?
This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07318558?
The interventions under investigation include: Bevacizumab (DRUG), Rescue Medications (DRUG), Sacituzumab tirumotecan (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07318558?
This trial is sponsored by Merck Sharp & Dohme, which has 741 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07318558 being conducted?
This trial has 9 study locations across Florida, Iwate, Tokyo, Seoul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.